Those will pay off tomorrow.
GBA Presents: THE GREEN MARKET
- Thread starter stonedinvestor
- Start date
more like vz's bomb stock. period.
pos.
Stoney!
Buy Abbott.
It was up nicely today.
$123.31
Every company in the 1st world is giving their employees the ultimatum... get the vax or do weekly (or more) testing.
Abbott's is the best and cheapest.
OSUR may have one, but Fortune 500 companies will go with Abbott.
2 for $22
ABT------> $123.31
Buy Abbott.
It was up nicely today.
$123.31
Every company in the 1st world is giving their employees the ultimatum... get the vax or do weekly (or more) testing.
Abbott's is the best and cheapest.
OSUR may have one, but Fortune 500 companies will go with Abbott.
2 for $22
ABT------> $123.31
Granny says BUY!
Abbott Reports Third-Quarter 2021 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance
- Third-quarter sales growth of 23.4 percent; organic sales growth of 22.4 percent
- GAAP diluted EPS from continuing operations growth of 69.6 percent; adjusted diluted EPS growth of 42.9 percent
- Global COVID-19 testing-related sales were $1.9 billion in the third quarter
- Excluding COVID-19 testing-related sales, third-quarter sales grew 11.7 percent on both a reported and organic basis compared to sales in 2019
- Continues to strengthen portfolio with several new product approvals
++++++++++++++++++++++++
Third-quarter sales of $10.9 billion increased 23.4 percent on a reported basis and 22.4 percent on an organic basis, which excludes the impact of foreign exchange.
Third-quarter GAAP diluted EPS was $1.17 and adjusted diluted EPS, which excludes specified items, was $1.40, reflecting 42.9 percent growth versus the prior year.
Abbott projects full-year 2021 diluted EPS from continuing operations on a GAAP basis of $3.55 to $3.65 and full-year adjusted diluted EPS from continuing operations of $5.00 to $5.10, reflecting growth of 38.4 percent at the mid-point versus prior year.
In August, Abbott announced U.S. FDA approval of its Amplatzer® Amulet® device, which offers immediate closure of the left atrial appendage – an area in the heart where blood clots can form.
In August, Abbott announced results of the company's GUIDE-HF clinical trial, which showed Abbott's CardioMEMS® remote monitoring system can improve care for more patients living with heart failure. Abbott filed a Premarket Approval (PMA) supplement with the FDA for consideration of an expanded indication for CardioMEMS.
In September, Abbott announced U.S. FDA approval of its Portico® with FlexNav® transcatheter aortic valve replacement (TAVR) system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery.
During the third quarter, Abbott acquired Walk Vascular, LLC, a commercial-stage medical device company with a minimally invasive thrombectomy system designed to remove peripheral blood clots.
"We achieved another quarter of strong growth overall and across all four of our major business areas," said Robert B. Ford, president and chief executive officer, Abbott. "We're particularly pleased with the continued advancements of our new product pipeline, including several recent launches in large, high-growth markets."
Abbott Reports Third-Quarter 2021 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance
- Third-quarter sales growth of 23.4 percent; organic sales growth of 22.4 percent
- GAAP diluted EPS from continuing operations growth of 69.6 percent; adjusted diluted EPS growth of 42.9 percent
- Global COVID-19 testing-related sales were $1.9 billion in the third quarter
- Excluding COVID-19 testing-related sales, third-quarter sales grew 11.7 percent on both a reported and organic basis compared to sales in 2019
- Continues to strengthen portfolio with several new product approvals
++++++++++++++++++++++++
Third-quarter sales of $10.9 billion increased 23.4 percent on a reported basis and 22.4 percent on an organic basis, which excludes the impact of foreign exchange.
Third-quarter GAAP diluted EPS was $1.17 and adjusted diluted EPS, which excludes specified items, was $1.40, reflecting 42.9 percent growth versus the prior year.
Abbott projects full-year 2021 diluted EPS from continuing operations on a GAAP basis of $3.55 to $3.65 and full-year adjusted diluted EPS from continuing operations of $5.00 to $5.10, reflecting growth of 38.4 percent at the mid-point versus prior year.
In August, Abbott announced U.S. FDA approval of its Amplatzer® Amulet® device, which offers immediate closure of the left atrial appendage – an area in the heart where blood clots can form.
In August, Abbott announced results of the company's GUIDE-HF clinical trial, which showed Abbott's CardioMEMS® remote monitoring system can improve care for more patients living with heart failure. Abbott filed a Premarket Approval (PMA) supplement with the FDA for consideration of an expanded indication for CardioMEMS.
In September, Abbott announced U.S. FDA approval of its Portico® with FlexNav® transcatheter aortic valve replacement (TAVR) system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery.
During the third quarter, Abbott acquired Walk Vascular, LLC, a commercial-stage medical device company with a minimally invasive thrombectomy system designed to remove peripheral blood clots.
"We achieved another quarter of strong growth overall and across all four of our major business areas," said Robert B. Ford, president and chief executive officer, Abbott. "We're particularly pleased with the continued advancements of our new product pipeline, including several recent launches in large, high-growth markets."
Stoney!
My proprietary VZ software has finally given me a flashing green light.
Good thing VZ doesn't listen to your cut and paste analyst upgrades.
QDEL now has the blessing.
$131
Earnings on 11/4
- le savante
i think it's a fine pick. the problem is the market/shorts/algos, it just kills this stuff until there are actually earnings, etc, to keep it honest. one day this stock that you can't give away will suddenly become the thing everyone wants.
Hey I screwed up I had a tip yesterday on CRocs and I didn't pass it along. It wasn't much of a tip it was an upgrade stating they had no supply chin issues I didn't act because FL said the same thing and sank but I got caught short because CROcs reported the next day and is up 11% I owe you one.- stoney
American Air: Business travel wants to return, sees 'enormous' pent-up demand 08:36 AAL
They try and use past history now to keep you in. Every situation is different. This situation says the Oct Jobs report will be STRONG. I have a feeling that all those folks who did not go back to work are slowly running out of money and eyeing the holidays. They are lots of jobs available and once a few go for them it will become a landslide. The tipping point to that landslide comes in the Oct Jobs report. Maybe Van can figure out the exact day but you want to be positioned with 10% cash or even against the market as the celebration of jobs fades and people realize the Fed said even a moderately good jobs report would be enough to start draining the liquidity.~stoney
They try and use past history now to keep you in. Every situation is different. This situation says the Oct Jobs report will be STRONG. I have a feeling that all those folks who did not go back to work are slowly running out of money and eyeing the holidays. They are lots of jobs available and once a few go for them it will become a landslide. The tipping point to that landslide comes in the Oct Jobs report. Maybe Van can figure out the exact day but you want to be positioned with 10% cash or even against the market as the celebration of jobs fades and people realize the Fed said even a moderately good jobs report would be enough to start draining the liquidity.~stoney
Stoney!
My proprietary VZ software has finally given me a flashing green light.
Good thing VZ doesn't listen to your cut and paste analyst upgrades.
I should of known Van would figure it out... Yes there is no proprietary software installed by a Green haired punk rocker-- it's just me and I begin drinking during market hours sometimes. Who would listen to me? So I tell my friends and family it's the software making me raise cash and they don't ask questions.
My proprietary VZ software has finally given me a flashing green light.
Good thing VZ doesn't listen to your cut and paste analyst upgrades.
I should of known Van would figure it out... Yes there is no proprietary software installed by a Green haired punk rocker-- it's just me and I begin drinking during market hours sometimes. Who would listen to me? So I tell my friends and family it's the software making me raise cash and they don't ask questions.